BridgeBio Pharma Valuation
| BBIO Stock | USD 75.85 0.60 0.80% |
At this time, the firm appears to be fairly valued. BridgeBio Pharma shows a prevailing Real Value of $73.83 per share. The current price of the firm is $75.85. Our model approximates the value of BridgeBio Pharma from analyzing the firm fundamentals such as Current Valuation of 15.64 B, profit margin of (2.25) %, and Return On Equity of -17.9 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting BridgeBio Pharma's valuation include:
Price Book 123.6828 | Enterprise Value | Enterprise Value Ebitda (9.40) | Price Sales 40.7596 | Enterprise Value Revenue 44.1959 |
Fairly Valued
Today
Please note that BridgeBio Pharma's price fluctuation is very steady at this time. Calculation of the real value of BridgeBio Pharma is based on 3 months time horizon. Increasing BridgeBio Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BridgeBio Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BridgeBio Stock. However, BridgeBio Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 75.85 | Real 73.83 | Target 98.3 | Hype 75.85 |
The intrinsic value of BridgeBio Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BridgeBio Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BridgeBio Pharma helps investors to forecast how BridgeBio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BridgeBio Pharma more accurately as focusing exclusively on BridgeBio Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use BridgeBio Pharma's intrinsic value based on its ongoing forecasts of BridgeBio Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against BridgeBio Pharma's closest peers.
BridgeBio Pharma Cash |
|
BridgeBio Revenue by Product
BridgeBio Pharma Total Value Analysis
BridgeBio Pharma is currently forecasted to have valuation of 15.64 B with market capitalization of 14.42 B, debt of 1.73 B, and cash on hands of 715.71 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the BridgeBio Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
15.64 B | 14.42 B | 1.73 B | 715.71 M |
BridgeBio Pharma Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.05. BridgeBio Pharma recorded a loss per share of 4.21. The entity had not issued any dividends in recent years. Based on the key measurements obtained from BridgeBio Pharma's financial statements, BridgeBio Pharma may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.BridgeBio Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BridgeBio Pharma has an asset utilization ratio of 24.14 percent. This suggests that the Company is making $0.24 for each dollar of assets. An increasing asset utilization means that BridgeBio Pharma is more efficient with each dollar of assets it utilizes for everyday operations.BridgeBio Pharma Profitability Analysis
Based on the key profitability measurements obtained from BridgeBio Pharma's financial statements, BridgeBio Pharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess BridgeBio Pharma's ability to earn profits and add value for shareholders.Net Loss | First Reported 2018-03-31 | Previous Quarter -181.9 M | Current Value -182.7 M | Quarterly Volatility 62.1 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.0 | 1.13 |
|
|
For BridgeBio Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BridgeBio Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BridgeBio Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BridgeBio Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BridgeBio Pharma over time as well as its relative position and ranking within its peers.
BridgeBio Pharma Earnings per Share Projection vs Actual
The next projected EPS of BridgeBio Pharma is estimated to be -0.415 with future projections ranging from a low of -0.445 to a high of -0.4. BridgeBio Pharma's most recent 12-month trailing earnings per share (EPS TTM) is at -4.21. Please be aware that the consensus of earnings estimates for BridgeBio Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.BridgeBio Pharma Earnings Estimation Breakdown
The calculation of BridgeBio Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of BridgeBio Pharma is estimated to be -0.415 with the future projection ranging from a low of -0.445 to a high of -0.4. Please be aware that this consensus of annual earnings estimates for BridgeBio Pharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.45 Lowest | Expected EPS | -0.4 Highest |
BridgeBio Pharma Earnings Projection Consensus
Suppose the current estimates of BridgeBio Pharma's value are higher than the current market price of the BridgeBio Pharma stock. In this case, investors may conclude that BridgeBio Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and BridgeBio Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 21 | 56.89% | 0.0 | -0.415 | -4.21 |
BridgeBio Pharma Ownership Allocation
BridgeBio Pharma holds a total of 191.63 Million outstanding shares. The majority of BridgeBio Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BridgeBio Pharma to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BridgeBio Pharma. Please pay attention to any change in the institutional holdings of BridgeBio Pharma as this could imply that something significant has changed or is about to change at the company. Also note that nearly six million nine hundred seventy-five thousand two hundred twenty-two invesors are currently shorting BridgeBio Pharma expressing very little confidence in its future performance.BridgeBio Pharma Profitability Analysis
The company reported the previous year's revenue of 221.9 M. Net Loss for the year was (543.35 M) with profit before overhead, payroll, taxes, and interest of 338.84 M.About BridgeBio Pharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of BridgeBio Pharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of BridgeBio Pharma based exclusively on its fundamental and basic technical indicators. By analyzing BridgeBio Pharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of BridgeBio Pharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of BridgeBio Pharma. We calculate exposure to BridgeBio Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BridgeBio Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 250.7 M | 263.3 M | |
| Pretax Profit Margin | (2.81) | (2.95) | |
| Operating Profit Margin | (3.07) | (3.23) | |
| Net Loss | (2.78) | (2.92) | |
| Gross Profit Margin | 1.13 | 1.00 |
BridgeBio Pharma Current Valuation Indicators
BridgeBio Pharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final BridgeBio Pharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BridgeBio Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BridgeBio Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BridgeBio Pharma's worth.When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Will Biotechnology sector continue expanding? Could BridgeBio diversify its offerings? Factors like these will boost the valuation of BridgeBio Pharma. Projected growth potential of BridgeBio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every BridgeBio Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.21) | Revenue Per Share | Quarterly Revenue Growth 43.18 | Return On Assets | Return On Equity |
BridgeBio Pharma's market price often diverges from its book value, the accounting figure shown on BridgeBio's balance sheet. Smart investors calculate BridgeBio Pharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since BridgeBio Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between BridgeBio Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BridgeBio Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.